1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants

 
• By Jessica Merrill

The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.

infant
A RSV vaccine was approved by FDA to protect infants • Source: Shutterstock

Pfizer Inc.’s respiratory syncytial virus (RSV) vaccine Abrysvo was approved by the US Food and Drug Administration to be administered to pregnant women to protect infants at birth, a first for vaccine development.

Abrysvo had already been approved by the FDA for older adults in May and recommended for use by the Centers for Disease Control’s Advisory Committee on Immunization Practices (ACIP) in those patients, along with GSK plc’s competing vaccine Arexvy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.